The Phase 3 clinical trial (NCT05047263) for finerenone, also known as Kerendia, reached primary completion on 2025-12-31. This study investigated the safety and efficacy of finerenone in adult participants diagnosed with non-diabetic chronic kidney disease.
Background
Chronic kidney disease (CKD) is a significant health concern, and researchers are actively seeking improved treatments, particularly for patients with non-diabetic CKD. Finerenone (Kerendia) is an investigational treatment being developed to address this need. It is designed to help individuals with long-lasting kidney disease. The drug's mechanism involves blocking a hormone called aldosterone, which is known to contribute to injury and inflammation in the heart and kidneys, playing a role in the progression of CKD.
Trial design
The Phase 3 clinical trial, officially titled "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease" (NCT05047263), was designed as a study to evaluate both the efficacy and safety profile of finerenone. The study enrolled a total of 1584 adult participants who had been diagnosed with non-diabetic chronic kidney disease. Participants in the trial received either the investigational drug finerenone or a placebo, allowing for a comparative assessment of the treatment's effects.
What this means
The primary completion of this Phase 3 trial for finerenone marks a critical milestone in its development for non-diabetic chronic kidney disease. This event indicates that all necessary patient data for the primary endpoints have been collected. The next crucial step will involve the comprehensive analysis of this extensive dataset to thoroughly assess the drug's safety and efficacy. The outcomes of this analysis will be pivotal in determining the potential of finerenone as a new therapeutic option and will guide future decisions regarding regulatory submissions and its potential availability to patients.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05047263, titled "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease," was posted on 2025-12-31 on clinicaltrials.gov.